Concurrent measures of total and integrated HIV DNA monitor reservoirs and ongoing replication in eradication trials

Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwards

(2012) John M. Murray et al.   AIDS

Directly Infected Resting CD4+T Cells Can Produce HIV Gag without Spreading Infection in a Model of HIV Latency

(2012) Matthew J. Pace et al.   PLoS Pathogens

A Randomized, Controlled Trial of Raltegravir Intensification in Antiretroviral-treated, HIV-infected Patients with a Suboptimal CD4+ T Cell Response

(2011) Hiroyu Hatano et al.   JOURNAL OF INFECTIOUS DISEASES

Relationship Between Residual Plasma Viremia and the Size of HIV Proviral DNA Reservoirs in Infected Individuals Receiving Effective Antiretroviral Therapy

(2011) Tae-Wook Chun et al.   JOURNAL OF INFECTIOUS DISEASES

Disulfiram Reactivates Latent HIV-1 in a Bcl-2-Transduced Primary CD4+ T Cell Model without Inducing Global T Cell Activation

(2011) S. Xing et al.   JOURNAL OF VIROLOGY

Rapid Turnover of 2-LTR HIV-1 DNA during Early Stage of Highly Active Antiretroviral Therapy

(2011) Weijun Zhu et al.   PLoS One

Engineering HIV-Resistant Human CD4+ T Cells with CXCR4-Specific Zinc-Finger Nucleases

(2011) Craig B. Wilen et al.   PLoS Pathogens

Elite Suppressors Harbor Low Levels of Integrated HIV DNA and High Levels of 2-LTR Circular HIV DNA Compared to HIV+ Patients On and Off HAART

(2011) Erin H. Graf et al.   PLoS Pathogens

Episomal Viral cDNAs Identify a Reservoir That Fuels Viral Rebound after Treatment Interruption and That Contributes to Treatment Failure

(2011) Mark Sharkey et al.   PLoS Pathogens

Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy

(2010) Steven A Yukl et al.   AIDS

Short‐Course Raltegravir Intensification Does Not Reduce Persistent Low‐Level Viremia in Patients with HIV‐1 Suppression during Receipt of Combination Antiretroviral Therapy

(2010) D. McMahon et al.   CLINICAL INFECTIOUS DISEASES

Infrequent Recovery of HIV from but Robust Exogenous Infection of Activated CD4+T Cells in HIV Elite Controllers

(2010) B. Julg et al.   CLINICAL INFECTIOUS DISEASES

Differences in HIV Burden and Immune Activation within the Gut of HIV‐Positive Patients Receiving Suppressive Antiretroviral Therapy

(2010) Steven A. Yukl et al.   JOURNAL OF INFECTIOUS DISEASES

Characterization of the Alpha Interferon-Induced Postentry Block to HIV-1 Infection in Primary Human Macrophages and T Cells

(2010) C. Goujon et al.   JOURNAL OF VIROLOGY

HIV-1 Continues To Replicate and Evolve in Patients with Natural Control of HIV Infection

(2010) H. Mens et al.   JOURNAL OF VIROLOGY

Control of HIV-1 in Elite Suppressors despite Ongoing Replication and Evolution in Plasma Virus

(2010) K. A. O'Connell et al.   JOURNAL OF VIROLOGY

HIV Persistence and the Prospect of Long-Term Drug-Free Remissions for HIV-Infected Individuals

(2010) D. Trono et al.   SCIENCE

Patients on HAART often have an excess of unintegrated HIV DNA: Implications for monitoring reservoirs

(2010) Luis M. Agosto et al.   VIROLOGY

The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial

(2010) Rajesh T. Gandhi et al.   PLOS MEDICINE

HIV reservoirs, latency, and reactivation: Prospects for eradication

(2009) Viktor Dahl et al.   ANTIVIRAL RESEARCH

Detecting HIV-1 integration by repetitive-sampling Alu-gag PCR

(2009) Megan K. Liszewski et al.   METHODS

HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation

(2009) Nicolas Chomont et al.   NATURE MEDICINE

Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs

(2009) Mayte Coiras et al.   NATURE REVIEWS MICROBIOLOGY

Long-Term Control of HIV byCCR5Delta32/Delta32 Stem-Cell Transplantation

(2009) Gero Hütter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy

(2009) J. B. Dinoso et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Challenge of Finding a Cure for HIV Infection

(2009) D. D. Richman et al.   SCIENCE

Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection

(2008) Lin Shen et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Dynamics of Total, Linear Nonintegrated, and Integrated HIV‐1 DNA In Vivo and In Vitro

(2008) Kersten K. Koelsch et al.   JOURNAL OF INFECTIOUS DISEASES

Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy

(2008) S. Palmer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A more precise HIV integration assay designed to detect small differences finds lower levels of integrated DNA in HAART treated patients

(2008) Jianqing J. Yu et al.   VIROLOGY